GLP-1 receptor agonists – China In-Depth – GLP-1 receptor agonists – China In-Depth – China

Type 2 diabetes and obesity are some of the biggest health challenges in Mainland China. Even though several drug classes have been available to treat these patients, very few have been able to improve the diabetes control rate or offer weight loss or cardiovascular benefits to patients. The anticipated launch and uptake of several GLP-1 receptor agonists in China—particularly oral semaglutide (Novo Nordisk’s Rybelsus) and tirzepatide (Eli Lilly)—and the incorporation of these therapies into China’s National Reimbursement Drug List (NRDL) will be the key drivers of growth in the T2D and obesity markets in China. Additionally, following the recent reforms in China’s regulatory and reimbursement landscape, manufacturers—both domestic and multinational—will be increasingly incentivized to enter China’s healthcare market over the coming years. Thus, significant commercial opportunity will exist for novel GLP-1 receptor agonists to treat patients suffering with metabolic and cardiovascular disorders in China.


  • How large is China’s GLP-1-receptor-agonist eligible patient population, and how will the treatment rates by GLP-1 receptor agonists in China change during the forecast period?
  • Which are the most commercially relevant drugs in China’s GLP-1 receptor agonist market and why? What are interviewed experts’ insights into current treatment options?
  • What are the market access considerations for key emerging GLP-1 receptor agonists in China? What sales / uptake could these agents secure? What are interviewed experts’ opinions of these therapies?
  • What are the key drivers and constraints in China’s GLP-1 receptor agonist therapy market, and how will the market evolve over the forecast period?


China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.



Primary Research

Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 50 specialists including endocrinologists, hepatologists, gastroenterologists, and cardiologists


Diagnosed prevalence of T2D, NASH, obesity, heart failure, and PAD in urban versus rural China; clinically relevant and commercially relevant drug-treatable populations


10-year, annualized, drug-level sales and patient share of key GLP-1 receptor agonists through 2031, based on primary and secondary market research to formulate bottom-up assumptions

Emerging Therapies

Phase III/PR: 10+ drugs; Phase II: 5+ drugs; coverage of select preclinical and Phase I products